AEON Biopharma (AEON) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
9 Jul, 2026Management team and governance
President and CEO is Robert Bancroft, who also serves as Principal Executive Officer and Director.
Chief Accounting Officer is Jennifer Sy, serving as Principal Accounting Officer.
Chief Financial Officer is John Bencich, serving as Principal Financial Officer.
Board includes Jost Fischer (Chairman), Robert Palmisano, Shelley Thunen, Eric Carter, Seongsoo Park, and Marc Forth.
Offering details and pricing
Registration statement filed for Class A common stock, $0.0001 par value per share.
Five-Year Milestone Warrants registered at 115% of the assumed public offering price.
Incremental registration fee paid for the increased aggregate offering price.
Securities may be offered on a delayed or continuous basis under Rule 415.
Underwriters and syndicate
Underwriting Agreement dated January 6, 2025, with Aegis Capital Corp.
Sales Agreement dated August 14, 2024, with Leerink Partners LLC.
Latest events from AEON Biopharma
- Raises $11M via equity and warrants to fund biosimilar development, but faces major financial risk.AEON
Registration filing8 Jul 2026 - ABP-450 aims to disrupt BOTOX®'s dominance with full-label biosimilarity and broad market access.AEON
Corporate presentation14 May 2026 - Q1 2026 net loss was $11.8M; positive FDA feedback and debt reduction support future plans.AEON
Q1 202614 May 2026 - Vote on director elections and auditor ratification at the June 2026 annual meeting.AEON
Proxy filing29 Apr 2026 - Shareholders will vote on director elections and auditor ratification, with Daewoong as a key stakeholder.AEON
Proxy filing29 Apr 2026 - Positive biosimilarity results, FDA support, and improved liquidity position ABP-450 for next steps.AEON
Q4 202530 Mar 2026 - ABP-450 targets BOTOX's dominance with a clinically identical, cost-saving biosimilar.AEON
Corporate presentation30 Mar 2026 - Registers 51.3M shares for resale as it seeks U.S. entry for a BOTOX® biosimilar amid going concern risk.AEON
Registration Filing9 Feb 2026 - Shareholders to vote on key financings and equity plan as company seeks biosimilar funding.AEON
Proxy Filing29 Dec 2025